AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
US, Japan Reaffirm Strong Currency Coordination Amid Yen Volatility 
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income 
Goldman Sachs Delays Fed Rate Cut Forecast to 2026 Amid Rising Inflation Concerns 
US Stock Futures Hold Steady Ahead of CPI Data and Iran Conflict Concerns 
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases 
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Asian Stocks Rise Despite Middle East Tensions as Chipmakers Boost Markets 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
K+S Raises 2026 Earnings Outlook After Strong Q1 Results 
Oil Prices Rise as Dollar Gains Ahead of Key U.S. Inflation Data 
CSL Shares Crash as Profit Warning and $5 Billion Impairment Shake Investors 
GOP Lawmakers Probe Sam Altman and OpenAI Ahead of Potential IPO 
SK bioscience Co. will invest $1.79 billion by 2027 to expand its contract manufacturing capabilities to strengthen its readiness for the next pandemic, expand its overseas operations, and seize new business opportunities.
The proposed investment is twice the amount the company had spent in the past five years.
Of the total investment, t half would be spent on research and development (R&D) and the construction of a new R&D campus in Songdo, Incheon, which is expected to be completed in 2025.
SK bioscience has manufactured the COVID-19 vaccines of AstraZeneca and Novavax in South Korea under a partnership deal.
The company is seeking to ink deals with major pharmaceutical companies within the year, according to SK bioscience CEO Ahn Jae-yong.
"A deal could come as early as within the first half of this year," he said.
Also, the company has been looking for a possible merger deal in the United States in the field of cell and gene therapy.
The company swung to a deficit for the January-March period as waning demand led to a drop in the production of licensed COVID-19 vaccines. Its loss amounted to 29.2 billion won, compared with a profit of 23.8 billion won a year ago.
Ahn expected the company to make a turnaround in three years after investing aggressively in building up the foundations for future growth.
